Your shopping cart is currently empty

PPARγ agonist19 (Compound 5e) is a PPARγ agonist with an IC50 of 11.27 μM for COX-1 and 0.05 μM for COX-2. It enhances glucose uptake in rat hemidiaphragm assays more effectively than pioglitazone. Additionally, PPARγ agonist19 reduces hyperglycemia and insulin resistance in type 2 diabetic rat models and protects against renal and lipid damage caused by metabolic dysfunction.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | PPARγ agonist19 (Compound 5e) is a PPARγ agonist with an IC50 of 11.27 μM for COX-1 and 0.05 μM for COX-2. It enhances glucose uptake in rat hemidiaphragm assays more effectively than pioglitazone. Additionally, PPARγ agonist19 reduces hyperglycemia and insulin resistance in type 2 diabetic rat models and protects against renal and lipid damage caused by metabolic dysfunction. |
| Targets&IC50 | COX-1:11.27 μM |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.